Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C21H27N5O2S |
Molar mass | 413.54 g·mol−1 |
3D model ( JSmol) | |
| |
|
Lupitidine ( INN; lupitidine hydrochloride ( USAN); development code SKF-93479) is a long-acting H2 receptor antagonist [1] developed by Smith, Kline & French and described as an antiulcerogenic that was never marketed. [2] It was shown to inhibit nocturnal gastric acid secretion [3] and, in experiments on rodents, produced diffuse neuroendocrine cell hyperplasia and an increase in multifocal glandular hyperplasia due to hypergastrinemia resulting from the pharmacological suppression of gastric acid secretion. [4]
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C21H27N5O2S |
Molar mass | 413.54 g·mol−1 |
3D model ( JSmol) | |
| |
|
Lupitidine ( INN; lupitidine hydrochloride ( USAN); development code SKF-93479) is a long-acting H2 receptor antagonist [1] developed by Smith, Kline & French and described as an antiulcerogenic that was never marketed. [2] It was shown to inhibit nocturnal gastric acid secretion [3] and, in experiments on rodents, produced diffuse neuroendocrine cell hyperplasia and an increase in multifocal glandular hyperplasia due to hypergastrinemia resulting from the pharmacological suppression of gastric acid secretion. [4]